Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance
- PMID: 11803074
- DOI: 10.1016/s0264-410x(01)00435-2
Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance
Abstract
Measles and mumps, but not rubella, outbreaks have been reported amongst populations highly vaccinated with a single dose of measles-mumps-rubella (MMR) vaccine. Repeated experience has shown that a two-dose regime of measles vaccine is required to eliminate measles. This paper reports the effect of the first and second MMR doses on specific antibody levels in a variety of populations.2-4 years after receiving a first dose of MMR vaccine at age 12-18 months, it was found that a large proportion of pre-school children had measles (19.5%) and mumps (23.4%) IgG antibody below the putative level of protection. Only a small proportion (4.6%) had rubella antibody below the putative protective level. A total of 41% had negative or equivocal levels to one or more antigens. The proportion measles antibody negative (but not rubella or mumps) was significantly higher in children vaccinated at 12 months of age than at 13-17 months. There was no evidence for correlation of seropositivity to each antigen, other than that produced by a small excess of children (1%) negative to all three antigens. After a second dose of MMR, the proportion negative to one or more antigens dropped to <4%. Examination of national serosurveillance data, found that following an MR vaccine campaign in cohorts that previously received MMR, both measles and rubella antibody levels were initially boosted but declined to pre-vaccination levels within 3 years. Our study supports the policy of administering a second dose of MMR vaccine to all children. However, continued monitoring of long-term population protection will be required and this study suggests that in highly vaccinated populations, total measles (and rubella) IgG antibody levels may not be an accurate reflection of protection. Further studies including qualitative measures, such as avidity, in different populations are merited and may contribute to the understanding of MMR population protection.
Similar articles
-
Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.Arch Iran Med. 2013 Jan;16(1):38-41. Arch Iran Med. 2013. PMID: 23273235
-
[Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].Zhonghua Yu Fang Yi Xue Za Zhi. 2017 Apr 6;51(4):336-340. doi: 10.3760/cma.j.issn.0253-9624.2017.04.011. Zhonghua Yu Fang Yi Xue Za Zhi. 2017. PMID: 28395468 Chinese.
-
Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.J Infect Dis. 2016 Jun 15;213(12):2005-13. doi: 10.1093/infdis/jiw058. Epub 2016 Feb 9. J Infect Dis. 2016. PMID: 26908733
-
Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.Drugs. 2003;63(19):2107-26. doi: 10.2165/00003495-200363190-00012. Drugs. 2003. PMID: 12962524 Review.
-
MMR vaccination and disease elimination: the Finnish experience.Expert Rev Vaccines. 2010 Sep;9(9):1045-53. doi: 10.1586/erv.10.99. Expert Rev Vaccines. 2010. PMID: 20822347 Review.
Cited by
-
Timely measles vaccination in Tianjin, China: a cross-sectional study of immunization records and mothers.BMC Public Health. 2014 Aug 29;14:888. doi: 10.1186/1471-2458-14-888. BMC Public Health. 2014. PMID: 25168663 Free PMC article.
-
Residual susceptibility to measles among young adults in Victoria, Australia following a national targeted measles-mumps-rubella vaccination campaign.BMC Public Health. 2007 Jun 8;7:99. doi: 10.1186/1471-2458-7-99. BMC Public Health. 2007. PMID: 17555601 Free PMC article.
-
Gender effects on humoral immune responses to smallpox vaccine.Vaccine. 2009 May 26;27(25-26):3319-23. doi: 10.1016/j.vaccine.2009.01.086. Epub 2009 Feb 5. Vaccine. 2009. PMID: 19200827 Free PMC article.
-
Prevention of measles, mumps and rubella: 40 years of global experience with M-M-RII.Hum Vaccin Immunother. 2021 Dec 2;17(12):5372-5383. doi: 10.1080/21645515.2021.2007710. Epub 2022 Feb 7. Hum Vaccin Immunother. 2021. PMID: 35130794 Free PMC article.
-
Immune response to second dose of MMR vaccine in Indian children.Indian J Med Res. 2011 Sep;134(3):302-6. Indian J Med Res. 2011. PMID: 21985812 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources